BioCentury
ARTICLE | Company News

Obesity, pain drugs approved in Japan

September 21, 2013 12:57 AM UTC

Norgine B.V. (Amsterdam, the Netherlands) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Oblean cetilistat to treat obesity in patients with both Type II diabetes and dyslipidemia. Norgine said it is the first approval for the product, which is expected to be launched early next year. Takeda has exclusive Japanese rights to the oral lipase inhibitor from Alizyme plc under a 2003 deal. Norgine acquired all rights to the product in 2009 from Alizyme, which went into administration. ...